
AbbVie offers better value while Eli Lilly leads in growth for 2027 pharma portfolios.
AbbVie and Eli Lilly are key pharmaceutical players with distinct strengths for 2027. AbbVie focuses on immunology and aesthetics with solid cash flow and a lower valuation, making it a value pick. Eli Lilly dominates metabolic health with rapid reve...




